Sugi Predict

Sugi Predict / Compounds / SCHEMBL1676918

SCHEMBL1676918

SCHEMBL1676918

CC(C)(C)OC(=O)CCCCCCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.35
▸ PRKCA P17252 6/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ HTR4 Q13639 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ PSMB8 P28062 1/20 0.31
▸ PSMB5 P28074 1/20 0.31
▸ TPSAB1 Q15661 1/20 0.31
▸ TPSD1 Q9BZJ3 1/20 0.31
▸ TPSG1 Q9NRR2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11920409 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL905426 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL11920413 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL557540 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL558796 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL25434198 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL905423 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL1510015 1.00 EPHX2 (0.39) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL15196458 0.95 EPHX2 (0.35) EPHX2SMN1; SMN2KMT2AHDAC1HDAC2
SCHEMBL8740492 0.92 STING1 (0.34) EPHX2KMT2AALDH1A1PSMB8PSMB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024134676-A1 PROCESS FOR THE PREPARATION OF TIRZEPATIDE DR. REDDY’S LABORATORIES LIMITED (IN) 2024-06-27 — — WO disclosed
US-20220135639-A1 PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST ELI LILLY AND COMPANY 2022-05-05 — — US disclosed
CN-105636979-B Novel derivatives of insulin analogues 诺和诺德股份有限公司 2020-01-10 — — CN disclosed
US-20190112348-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES NOVO NORDISK AS (DK) 2019-04-18 — — US disclosed
US-10259856-B2 Protease stabilized acylated insulin analogues NOVO NORDISK A/S (DK) 2019-04-16 — — US disclosed
US-9896496-B2 Derivative of an insulin analogue NOVO NORDISK A/S (DK) 2018-02-20 — — US disclosed
US-9896496-B2 Derivative of an insulin analogue NOVO NORDISK A/S (DK) 2018-02-20 — — US disclosed
US-9896496-B2 Derivative of an insulin analogue NOVO NORDISK A/S (DK) 2018-02-20 — — US disclosed
EP-3055325-B1 NOVEL DERIVATIVE OF AN INSULIN ANALOGUE NOVO NORDISK AS (DK) 2018-01-03 — — EP disclosed
US-9688737-B2 Protease stabilized acylated insulin analogues NOVO NORDISK A/S (DK) 2017-06-27 — — US disclosed
US-8637647-B2 Method of acylating a peptide or protein NOVO NORDISK A/S (DK) 2014-01-28 — — US disclosed
US-20110213131-A1 Method of Acylating a Peptide or Protein NOVO NORDISK A/S (DK) 2011-09-01 — — US disclosed
US-20110213131-A1 Method of Acylating a Peptide or Protein NOVO NORDISK A/S (DK) 2011-09-01 — — US disclosed
US-20110213131-A1 Method of Acylating a Peptide or Protein NOVO NORDISK A/S (DK) 2011-09-01 — — US disclosed
EP-2340049-A1 METHOD OF ACYLATING A PEPTIDE OR PROTEIN Novo Nordisk A/S (DK) 2011-07-06 — — EP disclosed
US-20110105720-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES NOVO NORDISK A/S (DK) 2011-05-05 — — US disclosed
US-20110098440-A1 Insulin Analogues with an Acyl and Alkylene Glycol Moiety NOVO NORDISK A/S (DK) 2011-04-28 — — US disclosed
US-20110098440-A1 Insulin Analogues with an Acyl and Alkylene Glycol Moiety NOVO NORDISK A/S (DK) 2011-04-28 — — US disclosed
US-20110098440-A1 Insulin Analogues with an Acyl and Alkylene Glycol Moiety NOVO NORDISK A/S (DK) 2011-04-28 — — US disclosed
WO-2010029159-A1 METHOD OF ACYLATING A PEPTIDE OR PROTEIN NOVO NORDISK A/S (DK) 2010-03-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105720-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES IAPP, IDE, LIPE EPHX2 4491/4885SMN1; SMN2 1083/4885KMT2A 2298/4885
US-20110098440-A1 Insulin Analogues with an Acyl and Alkylene Glycol Moiety IAPP, INSR, IGF1R EPHX2 4405/4885SMN1; SMN2 1613/4885KMT2A 418/4885
US-20110213131-A1 Method of Acylating a Peptide or Protein DNPEP, PTMA, ANPEP EPHX2 4021/4885SMN1; SMN2 3837/4885KMT2A 2645/4885
US-20220135639-A1 PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST GLP1R, GIPR, GPR119 EPHX2 2562/4885SMN1; SMN2 1387/4885KMT2A 2749/4885
US-20190112348-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES IAPP, IDE, LIPE EPHX2 4491/4885SMN1; SMN2 1083/4885KMT2A 2298/4885
US-10259856-B2 Protease stabilized acylated insulin analogues IAPP, IDE, LIPE EPHX2 4657/4885SMN1; SMN2 1218/4885KMT2A 2426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.